Search results for "Glyburide"

showing 10 items of 12 documents

Pharmacotherapy for gestational diabetes mellitus: still insulin, or what about sulfonylureas?

2018

Randomized trials have not focused on neonatal complications of glyburide for women with gestational diabetes.To compare oral glyburide vs subcutaneous insulin in prevention of perinatal complications in newborns of women with gestational diabetes.The Insulin Daonil trial (INDAO), a multicenter noninferiority randomized trial conducted between May 2012 and November 2016 (end of participant follow-up) in 13 tertiary care university hospitals in France including 914 women with singleton pregnancies and gestational diabetes diagnosed between 24 and 34 weeks of gestation.Women who required pharmacologic treatment after 10 days of dietary intervention were randomly assigned to receive glyburide …

AdultBlood Glucosemedicine.medical_specialtyendocrine system diseasesInjections Subcutaneousmedicine.medical_treatmentAdministration Oral030209 endocrinology & metabolism.OverweightInfant Newborn DiseasesFetal Macrosomia03 medical and health sciences0302 clinical medicinePharmacotherapyInsulin resistancePregnancyInternal medicineGlyburidemedicineHumansHypoglycemic AgentsInsulin030212 general & internal medicineFamily historyHyperbilirubinemiabusiness.industryInsulinInfant NewbornPregnancy Outcomenutritional and metabolic diseasesType 2 Diabetes MellitusGeneral Medicinemedicine.diseaseHypoglycemiafemale genital diseases and pregnancy complicationsGestational diabetesDiabetes GestationalEditorialEndocrinologyFemalemedicine.symptomMetabolic syndromebusinessAnnals of Translational Medicine
researchProduct

Modulation of adrenergic responses of human vas deferens by K+ channel inhibitors.

2010

Objectives The present study was designed to evaluate the role of K + channels in the adrenergic responses of human vas deferens as well as the intervention of dihydropyridine-sensitive Ca 2+ channels on modulation of adrenergic responses by K + channel inhibitors. Methods Ring segments of the epididymal part of the vas deferens were taken from 32 elective vasectomies and mounted in organ baths for isometric recording of tension. We then studied the effects of K + channel blockers on neurogenic and norepinephrine-induced contractile responses. Results Addition of tetraethylammonium (TEA, 10 −3 M), a nonspecific K + channel blocker, or charybdotoxin (10 −7 M), a nonselective inhibitor of lar…

AdultMalemedicine.medical_specialtyPotassium ChannelsCharybdotoxinCalcium Channels L-TypeCharybdotoxinNifedipineUrologyAdrenergicApaminGlibenclamidechemistry.chemical_compoundNorepinephrineVas DeferensNifedipineInternal medicineReceptors Adrenergic alpha-1GlyburidePotassium Channel BlockersMedicineHumansChannel blockerTetraethylammoniumIon Transportbusiness.industryVas deferensTetraethylammoniumMuscle SmoothElectric StimulationEndocrinologymedicine.anatomical_structurechemistryApaminPotassiumCalciumbusinessPeptidesmedicine.drugMuscle ContractionUrology
researchProduct

Comparison of the Effects of Glibenclamide on Metabolic Parameters, GLUT1 Expression, and Liver Injury in Rats With Severe and Mild Streptozotocin-In…

2012

Background and Objective. Glucose transport via GLUT1 protein could be one of additional mechanisms of the antidiabetic action of sulfonylureas. Here, the GLUT1 gene and the protein expression was studied in rats in the course of severe and mild streptozotocin-induced diabetes mellitus and under glibenclamide treatment. Material and Methods. Severe and mild diabetes mellitus was induced using different streptozotocin doses and standard or high fat chow. Rats were treated with glibenclamide (2 mg/kg daily, per os for 6 weeks). The therapeutic effect of glibenclamide was monitored by measuring several metabolic parameters. The GLUT1 mRNA and the protein expression in the kidneys, heart, and l…

Blood GlucoseMalemedicine.medical_specialtymedicine.medical_treatmentGene ExpressionDiabetes Mellitus ExperimentalGlibenclamideInternal medicineDiabetes mellitusGlyburideInsulin SecretionmedicineAnimalsHypoglycemic AgentsInsulinRats WistarLiver injuryGlucose Transporter Type 1Kidneybiologybusiness.industryInsulinGlucose transporternutritional and metabolic diseasesGeneral Medicinemedicine.diseaseStreptozotocinRatsSulfonylurea Compoundsmedicine.anatomical_structureEndocrinologyLiverProtein Biosynthesisglibenclamide; GLUT1; kidney; streptozotocin; expressionbiology.proteinGLUT1businessmedicine.drugMedicina; Volume 48; Issue 10; Pages: 78
researchProduct

Synthesis and evaluation of a glibenclamide glucose-conjugate: a potential new lead compound for substituted glibenclamide derivatives as islet imagi…

2007

The search for novel SUR1-ligands originates from the idea to influence the in vivo behaviour by adding new structural moieties to the glibenclamide structure while preserving its binding affinity. Important application of novel conjugates might be their use as radioactively labelled tracer probes in the non-invasive investigation of the islet mass. It is known that the imaging quality of a tracer could be improved by increasing its hydrophilicity, which leads to a reduced plasma protein binding and diminished the unspecific uptake by various organs. In this study the glucose molecule was chosen as a substitute of glibenclamide to enhance hydrophilicity. As expected glucose conjugation lead…

GlycosylationPotassium ChannelsTime FactorsPhysiologyReceptors DrugClinical BiochemistryPlasma protein bindingSulfonylurea ReceptorsBiochemistryBinding CompetitiveGlibenclamideCellular and Molecular Neurosciencechemistry.chemical_compoundIslets of LangerhansEndocrinologyIn vivoChlorocebus aethiopsGlyburidemedicineAnimalsHumansHypoglycemic AgentsInsulinPotassium Channels Inwardly Rectifyinggeographygeography.geographical_feature_categoryMolecular StructureLigand (biochemistry)IsletRatsGlucosechemistryBiochemistryCOS CellsATP-Binding Cassette TransportersLead compoundConjugatemedicine.drugRegulatory peptides
researchProduct

Capacitative Ca2+ entry associated with α1-adrenoceptors in rat aorta

1997

In rat aorta, depletion of internal Ca2+ stores by addition of noradrenaline (1 microM) induces a biphasic response (an initial phasic response and a tonic one) mediated by two different intracellular Ca2+ pools. This response cannot be repeated, suggesting a depletion of internal Ca2+ stores sensitive to noradrenaline. In absence of the agonist, this depletion is the signal for the entry of extracellular Ca2+, not only to refill the stores but also, under our experimental conditions, to activate the contractile proteins thus inducing an increase in the resting tone (IRT) that constitutes functional evidence of this Ca2+ entry. The ionic channels involved in the mechanism of the IRT have be…

MaleAgonistCromakalimmedicine.medical_specialtyPotassium Channelsmedicine.drug_classIn Vitro TechniquesTonic (physiology)NorepinephrineReceptors Adrenergic alpha-1medicine.arteryInternal medicineGlyburidePotassium Channel BlockersmedicineExtracellularAnimalsBenzopyransPyrrolesRats WistarCa2 entryAortaIonic ChannelsPharmacologyAortaChemistryGeneral MedicineTetraethylammonium CompoundsCalcium Channel BlockersRatsEndocrinologyMuscle TonusAlpha1 adrenoceptorBiophysicsCalciumNimodipineCalcium ChannelsIntracellularMuscle ContractionNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Effects of K(ATP) channel modulators on acetylcholine release from guinea-pig isolated atria and small intestine.

2002

The effects of K(ATP) channel blockers (glibenclamide, HMR 1883, HMR 1372) and openers (cromakalim, pinacidil, diazoxide) on the electrically-evoked (5 Hz) release of [(3)H]acetylcholine were studied in isolated guinea-pig atria and myenteric plexus-longitudinal muscle preparations which had been preincubated with [(3)H]choline. Atria: Cromakalim (0.3 microM and 1 microM), pinacidil (10 microM) and diazoxide (30 microM) significantly reduced the stimulation-evoked release of [(3)H]acetylcholine. The inhibition produced by cromakalim and pinacidil was prevented by 1 microM of either HMR 1883, HMR 1372 or glibenclamide. The blockers alone significantly increased the release at concentrations …

MaleCromakalimPotassium ChannelsGuinea PigsNeuromuscular JunctionMyenteric PlexusPharmacologyIn Vitro Techniqueschemistry.chemical_compoundGlyburideIntestine SmallmedicineDiazoxidePotassium Channel BlockersAnimalsChannel blockerHeart AtriaPharmacologySulfonamidesPinacidilDiazoxideThioureaPotassium channel blockerMuscle SmoothGeneral Medicinemusculoskeletal systemAtrial FunctionMyocardial ContractionHMR 1883Potassium channelAcetylcholinechemistryAnesthesiaPinacidilcardiovascular systemFemaleCromakalimAcetylcholinemedicine.drugNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

Increased Hypoxic Tolerance by Chemical Inhibition of Oxidative Phosphorylation: “Chemical Preconditioning”

1997

A short ischemic episode preceding sustained ischemia is known to increase tolerance against ischemic cell death. We report early-onset long-lasting neuroprotection against in vitro hypoxia by preceding selective chemical inhibition of oxidative phosphorylation: “chemical preconditioning.” The amplitude of CA1population spikes (psap) in hippocampal slices prepared from control animals (control slices) was 31 ± 27% (mean ± SD) upon 45-min recovery from 15-min in vitro hypoxia. In slices prepared from animals treated in vivo with 20 mg/kg 3-nitropropionate (3-np) 1–24 h prior to slice preparation (preconditioned slices), psap improved to 90 ± 15% (p < 0.01). Posthypoxic oxygen free radical…

MalePotassium ChannelsFree RadicalsPopulationIschemiaNerve Tissue ProteinsBiologyPharmacologyHippocampusNeuroprotectionOxidative PhosphorylationBrain Ischemia030218 nuclear medicine & medical imagingGlibenclamide03 medical and health sciencesAdenosine Triphosphate0302 clinical medicineSlice preparationIn vivoGlyburidemedicineAnimalsEnzyme InhibitorsRats WistarHypoxia BraineducationNeuronseducation.field_of_studyAntagonistHypoxia (medical)NADNitro Compoundsmedicine.diseaseCell HypoxiaRatsSuccinate DehydrogenaseNeuroprotective AgentsNeurologyAnesthesiaNeurology (clinical)Propionatesmedicine.symptomReactive Oxygen SpeciesCardiology and Cardiovascular Medicine030217 neurology & neurosurgerymedicine.drugJournal of Cerebral Blood Flow & Metabolism
researchProduct

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

2006

BACKGROUND: The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known. METHODS: We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving 4360 patients. The patients were treated for a median of 4.0 years. The primary outcome was the time to monotherapy failure, which was defined as a confirmed level of fasting plasma glucose of more than 180 mg per deciliter (10.0 mmol per liter), for rosiglitazone, as compared with metformin or glyburide. Prespecified secondary…

Malemedicine.medical_specialtyUrologyKaplan-Meier EstimateType 2 diabetesPharmacologyWeight GainRosiglitazoneGlibenclamidechemistry.chemical_compoundDouble-Blind MethodDiabetes mellitusGlyburidemedicineHumansHypoglycemic AgentsProportional Hazards ModelsGlycemicGlycated HemoglobinGlycemic efficacyWaist-Hip Ratiobusiness.industryCholesterol LDLGeneral MedicineMiddle Agedmedicine.diseaseMetforminMetforminTreatment OutcomeDiabetes Mellitus Type 2chemistryCardiovascular DiseasesFemaleThiazolidinedionesGlycated hemoglobinbusinessRosiglitazonemedicine.drugNew England Journal of Medicine
researchProduct

Diagnostic use of fructosamine assay in the control of type II diabetes mellitus.

1988

In an attempt to evaluate the usefulness of fructosamine assay in monitoring type II diabetes, 142 diabetic patients were investigated. Fructosamine values were found to be higher in patients on insulin treatment than on oral hypoglycemic agents. In order to evaluate the metabolic control by using the correlated variations of F, Gm and HbAlc, the patients were subdivided into many control classes: mean values of fructosamine were higher in poorly controlled patients. Fructosamine however correlated better with glycemia in patients with recent variations in metabolic state than HbAlc. It was concluded that fructosamine is a good index for short-term metabolic control, and if used in an integ…

Metabolic stateAdultBlood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentGastroenterologyType ii diabeteschemistry.chemical_compoundEndocrinologyPhenforminReference ValuesDiabetes mellitusInternal medicineGlyburideInternal MedicineMedicineHumansInsulinIn patientGlycated Hemoglobinbusiness.industryInsulinHexosaminesGeneral MedicineMiddle Agedmedicine.diseaseFructosamineEndocrinologychemistryDiabetes Mellitus Type 2Metabolic control analysisOral hypoglycemic agentsFructosamineFemalebusinessActa diabetologica latina
researchProduct

Emerging Therapeutic Strategies for Traumatic Spinal Cord Injury

2020

Spinal cord injury (SCI) is a debilitating neurologic condition with tremendous socioeconomic impact on affected individuals and the health care system. The treatment of SCI principally includes surgical treatment and marginal pharmacologic and rehabilitation therapies targeting secondary events with minor clinical improvements. This unsuccessful result mainly reflects the complexity of SCI pathophysiology and the diverse biochemical and physiologic changes that occur in the injured spinal cord. Once the nervous system is injured, cascades of cellular and molecular events are triggered at varying times. Although the cascade of tissue reactions and cell injury develops over a period of days …

Nervous systemmedicine.medical_specialtyCordmedicine.medical_treatmentSpinal cord injuryRegenerative MedicineMesenchymal Stem Cell TransplantationNeuroprotection03 medical and health sciences0302 clinical medicineNeural Stem CellsGlyburideGranulocyte Colony-Stimulating FactormedicineHumansHypoglycemic AgentsIntensive care medicineErythropoietinSpinal cord injurySpinal Cord InjuriesNeuronal PlasticityRehabilitationCombination treatmentsHepatocyte Growth Factorbusiness.industryNeurological RehabilitationDecompression SurgicalSpinal cordmedicine.diseaseNeuroregenerationNeuroprotectionClinical trialFibroblast Growth FactorsClinical trialmedicine.anatomical_structure030220 oncology & carcinogenesisIntercellular Signaling Peptides and ProteinsSurgeryNeuroregenerationSchwann CellsNeurology (clinical)business030217 neurology & neurosurgeryStem Cell TransplantationWorld Neurosurgery
researchProduct